Results for tag: "Dupixent"

Dupixent (dupilumab) is a biologic drug used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. It is a monoclonal antibody that works by blocking two proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in the inflammation and symptoms of atopic dermatitis. Dupixent is administered as an injection under the skin (subcutaneous) every two weeks. The Dupixent market is a rapidly growing segment of the dermatological drugs market. It is a highly competitive market, with several companies offering similar products. Dupixent is the first biologic drug approved for the treatment of atopic dermatitis, and it has been shown to be effective in reducing symptoms and improving quality of life for patients. Companies in the Dupixent market include Regeneron Pharmaceuticals, Sanofi, and AstraZeneca. Show Less Read more